Literature DB >> 11156227

Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.

M Ando1, H Minami, Y Ando, H Saka, S Sakai, M Yamamoto, Y Sasaki, K Shimokata, Y Hasegawa.   

Abstract

Creatinine clearance (Ccr) is widely used as a practical substitute for glomerular filtration rate (GFR) in the Calvert formula: carboplatin dose (mg) = target area under the concentration versus time curve (AUC, mg ml(-1) min) x [GFR (ml min(-1)) + 25]. However, it causes systematic overdosing when the creatinine levels are measured by an enzymatic peroxidase-antiperoxidase method (PAP-Cr). We previously suggested an amended dosing formula to adjust this overdosing: carboplatin dose (mg) = AUC (mg ml(-1) min) x [adjusted Ccr (ml min(-1)) + 25], where the Ccr was adjusted by adding 0.2 (mg dl(-1)) to serum PAP-Cr. In this study, we prospectively validated this formula in 55 patients from six institutions. Target AUC ranged from 3 to 7 mg ml(-1) min, and Ccr was measured by 24-h urine collection. Estimation of carboplatin clearance with the amended formula was unbiased [mean prediction error (MPE) +/- SE = 2.9 +/- 3.4%] and acceptably precise [root mean squared error, (RMSE) = 24.7%], whereas the Calvert formula using non-adjusted Ccr overpredicted carboplatin clearance systematically (MPE +/- SE = 24.9 +/- 4.9% and RMSE = 36.1%). The improvement in the bias and precision of the estimation was seen in all of the participating institutions as shown by decrease in the absolute value of MPE and RMSE for each institution. The Chatelut formula also highly overestimated carboplatin clearance when PAP-Cr was used, but the adjustment of PAP-Cr yielded a decrease in MPE by 30.4% and in RMSE by 21.3%. These results confirmed the necessity of adjusting the serum PAP-Cr in carboplatin dosing formulas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156227

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin.

Authors:  Fabienne Thomas; Sophie Séronie-Vivien; Laurence Gladieff; Florence Dalenc; Valérie Durrand; Laurence Malard; Thierry Lafont; Muriel Poublanc; Roland Bugat; Etienne Chatelut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy.

Authors:  Miho Tatematsu; Yoshinari Yasuda; Yoshiki Morita; Izumi Sakamoto; Kei Kurata; Tomohiko Naruse; Rhohei Yamamoto; Naotake Tsuboi; Waichi Sato; Enyu Imai; Seiichi Matsuo; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2012-05-23       Impact factor: 2.801

3.  Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing.

Authors:  Che Ry Hong; Hyoung Jin Kang; Seol Ju Moon; Jaeseong Oh; Kyung Taek Hong; Jung Yoon Choi; Kyung-Sang Yu; Hee Young Shin
Journal:  Bone Marrow Transplant       Date:  2019-08-28       Impact factor: 5.483

4.  Comparison of two methods for carboplatin dosing in children with retinoblastoma.

Authors:  Steven Allen; Matthew W Wilson; Amy Watkins; Catherine Billups; Ibrahim Qaddoumi; Barrett H Haik; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

Review 5.  Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Authors:  Shigeo Horie; Mototsugu Oya; Masaomi Nangaku; Yoshinari Yasuda; Yasuhiro Komatsu; Motoko Yanagita; Yuko Kitagawa; Hiroyuki Kuwano; Hiroyuki Nishiyama; Chikashi Ishioka; Hiromasa Takaishi; Hideki Shimodaira; Akira Mogi; Yuichi Ando; Koji Matsumoto; Daisuke Kadowaki; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2018-02       Impact factor: 2.801

6.  Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.

Authors:  Akihiro Tamiya; Motohiro Tamiya; Takayuki Shiroyama; Nobuhiko Saijo; Takeshi Nakatani; Shojiro Minomo; Taisuke Tsuji; Naoko Takeuchi; Naoki Omachi; Kanako Kurata; Hidekazu Suzuki; Norio Okamoto; Kyoichi Okishio; Tomonori Hirashima; Shinji Atagi
Journal:  Med Oncol       Date:  2015-01-25       Impact factor: 3.064

7.  Impact of Isotope Dilution Mass Spectrometry (IDMS) Standardization on Carboplatin Dose and Adverse Events.

Authors:  Justin Lawson; Jeffrey M Switchenko; Trevor McKibbin; R Donald Harvey
Journal:  Pharmacotherapy       Date:  2016-06       Impact factor: 4.705

8.  Evaluation of carboplatin dosage based on 4-variable modification of diet in renal disease equation.

Authors:  A Barry; R O'Cearbhaill; D Griffin; P Donnellan; M Keane; H Grimes
Journal:  Ir J Med Sci       Date:  2008-11-11       Impact factor: 1.568

9.  Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.

Authors:  G J Veal; J Errington; M J Tilby; A D J Pearson; A B M Foot; H McDowell; C Ellershaw; B Pizer; G M Nowell; D G Pearson; A V Boddy
Journal:  Br J Cancer       Date:  2007-02-13       Impact factor: 7.640

Review 10.  Carboplatin dosing for adult Japanese patients.

Authors:  Yuichi Ando; Tomoya Shimokata; Yoshinari Yasuda; Yoshinori Hasegawa
Journal:  Nagoya J Med Sci       Date:  2014-02       Impact factor: 1.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.